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Abstract: Background. Research into comorbidity of alcohol and cannabis use disorders has 25 
resulted in inconsistent findings, especially among simultaneous users, who used alcohol and 26 
cannabis together on a single occasion. This study investigated the association of alcohol and 27 
cannabis use disorders among simultaneous users using a network perspective, which considers 28 
direct relationships between symptoms.  29 
Methods. We used a subset of simultaneous alcohol and cannabis users driven from the 30 
representative population-based sample of young Swiss men Cohort Study on Substance Use Risk 31 
Factors (n=1,559 at baseline and n=991 at follow-up). Self-reported symptoms of alcohol and cannabis 32 
use disorders were collected. Network analyses included network estimation, visualization, and 33 
community detection tests.  34 
Results. Alcohol and cannabis use symptoms were separated in two distinct clusters, with few 35 
paths between them (eleven positive edges at baseline, three at follow-up). Withdrawal symptoms 36 
were likely to connect the two disorders at baseline, but not at follow-up. 37 
Conclusions. Alcohol and cannabis use disorders appeared as separate disorders among 38 
simultaneous users. Our findings mitigated previous findings on the detrimental association between 39 
alcohol and cannabis use. Future studies should incorporate network analyses as a means to study 40 
comorbidity in other community and clinical samples to confirm our preliminary findings. 41 
Keywords: addiction; alcohol; cannabis; C-SURF; marijuana; polydrug use. 42 
 43 
1. Introduction 44 
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Alcohol and cannabis is a common polydrug combination, and the potential detrimental effects 45 
on health of both drugs are elevated when the two types of substances are co-ingested (i.e., used at 46 
the same time so the effects of the two substances overlap) (1, 2). This definition allows capturing the 47 
interacting effects of substances, because the effects of the substances overlap, with a substance that 48 
may increase or decrease the effect of the other. Such combinations should be taken into account 49 
when studying polysubstance use, to achieve a better understanding of their detrimental health 50 
associations. Compared with the use of alcohol and cannabis separately, the use of both substances 51 
on a single occasion is associated with higher levels of substance use, engagement in risky or norm-52 
violating behaviors, and more substance-related problems, such as educational, legal, relational, and 53 
health problems (3-7). Simultaneous alcohol and cannabis use is also likely to increase the severity of 54 
alcohol and cannabis use disorders (6, 8). Therefore, simultaneous use should be an important public 55 
health concern. 56 
Besides, research on the relationships between alcohol and cannabis use has yielded inconsistent 57 
findings (9-11). There is a general acknowledgement on the fact that alcohol and cannabis use 58 
disorders are separate syndromes (12). However, when individuals use both substances 59 
(concurrently or simultaneously), cannabis is sometimes described as a substance that complements 60 
alcohol use and, at other times, as a substitute for alcohol use, while other studies have supported 61 
neither or both of these conceptions (9). These findings suggest that alcohol and cannabis use 62 
disorders may be interacting disorders. Research based on interventions’ outcome have also reported 63 
inconsistent findings. Some studies concluded that cannabis use and even low cannabis intake was 64 
associated with a lower percentage of days of abstinence (10, 12), but others showed that cannabis 65 
use did not decrease the efficacy of alcohol interventions (13, 14). Despite the absence of convincing 66 
evidence on the relationship between alcohol and cannabis use, complete abstinence from both 67 
substances is commonly recommended in treatment (15). Data-driven approaches of the comorbidity 68 
of alcohol and cannabis use are therefore needed to achieve a better understanding of their 69 
relationships and ultimately, to provide guidance for treatment. Simultaneous users should be at 70 
special focus because this is a common pattern of substance use and because disorders may be 71 
strongly interacting when both substances are used on the same occasion (2, 8). 72 
Investigating network structures to understand the relationships between symptoms of a 73 
disorder is a recent research field in clinical psychology and psychiatry (16, 17). The network 74 
perspective differs drastically from standard approaches and has contributed to mental health 75 
research by tackling several research questions related to the associations between several symptoms 76 
of a unique disorder, but also in the case of comorbidity (18). The network perspective supposes that 77 
a disorder is a dynamic system or network composed of symptoms that are directly related to one 78 
another (19). Therefore, a disorder is no longer considered as a latent construct that cause symptoms: 79 
it is composed of the symptoms themselves and of their direct relationships. The approach supposes 80 
that symptoms cluster in a nonarbitrary way, with direct and potentially causal symptom-symptom 81 
relationships (20). They are mutually interacting and may also be reciprocally reinforcing (20). 82 
Therefore, it offers a new way to understand disorders (17). Studying the comorbidity of two or more 83 
disorders from a network perspective entails two major advantages. First, it allows investigating the 84 
extent to which these two disorders have clear boundaries. If two disorders are clearly separated, one 85 
would expect two separate clusters of symptoms. Second, it is possible to explore pathways between 86 
the two disorders, with the potential existence of so-called bridge symptoms that create a path 87 
between two disorders (18, 21). For example, a previous study investigating the comorbidity of 88 
problematic Internet use and problem gambling concluded that problem gambling and problematic 89 
Internet use were separate disorders, but more strongly related for online gamblers in comparison 90 
with land-based gamblers (19). To answer this research question, the authors created two networks 91 
of symptoms of problematic Internet use and problem gambling, one for online gamblers and one for 92 
land-based gamblers and tested the strength of the relationships between disorders. Such studies 93 
provide a better overview of the relationships of multiple disorders and how they may interact and 94 
overlap. Thus, the network perspective offers a straightforward way to examine how different 95 
disorders may co-occur in a network structure, with interactions occurring between symptoms, 96 
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possibly irrespective of disorder boundaries (22, 23). Therefore, network-based analyses may provide 97 
new insights into the comorbidity of alcohol and cannabis use disorders. This perspective overcomes 98 
some issues of standard approaches, for example considering that symptoms are passive indicators 99 
of the syndrome and are independent from each other.  100 
Few studies have applied network analysis to the study of substance use disorders. An 101 
exploratory study focused on separate networks for different substances and showed that some 102 
symptoms of substance use disorders were more important (central) than others (24). This study 103 
provided a first glance into the structure of substance use disorders’ networks, but more 104 
investigations are needed to examine the relationships between several substance use disorders, 105 
especially among young adults for whom they represent a prevalent form of psychopathology (25, 106 
26). Another study investigated threshold of alcohol use disorder symptoms, but did not focus on 107 
comorbidity with other substance use disorders (27). 108 
The aim of this exploratory data-driven study was to use network analysis to investigate the 109 
comorbidity of alcohol and cannabis use disorders among simultaneous alcohol and cannabis users 110 
from a population-based sample of young men. Specifically, we investigated the extent to which 1) 111 
the symptoms of these two substances use disorders overlapped; and 2) whether some bridge 112 
symptoms between disorders could be identified. 113 
2. Materials and Methods  114 
2.1 Sample and procedures 115 
Data were collected in the two first waves of the Cohort Study on Substance Use and Risk Factors 116 
(C-SURF) (28), a longitudinal study designed to assess substance use patterns and associated 117 
consequences among young Swiss men. Participants were enrolled during mandatory conscription 118 
in three Swiss national military recruitment centers. There was no preselection for this conscription, 119 
so all young men around 20 years old were eligible for study inclusion. Participation was 120 
independent from the military recruitment. The three recruitment centers cover 21 out of 26 cantons 121 
of the country, including French- and German-speaking participants. A previous study on non-122 
response in C-SURF found non-response bias to be small (29). All subjects gave their informed 123 
consent for inclusion before they participated in the study. The study was conducted in accordance 124 
with the Declaration of Helsinki, and the protocol was approved by the the Lausanne University 125 
Medical School’s Clinical Research Ethics Committee (No. 15/07). 126 
Of the 7,556 conscripts who gave written consent to participate, 5,987 (79.2%) filled in the 127 
baseline questionnaire between September 2010 and March 2012. The follow-up took place on 128 
average 15 months later (2012-2013). A total of 6,020 participants completed the follow-up 129 
questionnaire, including participants who did not answer the baseline questionnaire. More detailed 130 
information on the sample is available elsewhere (28). As our secondary-data-analysis study focused 131 
on simultaneous alcohol and cannabis use, we selected participants who used both alcohol and 132 
cannabis in the same occasion. Participants were asked the following question in the baseline and 133 
follow-up questionnaire: “how often did you take alcohol along with cannabis (simultaneously) in 134 
the past twelve months? By “simultaneously”, we mean shortly before or after drinking alcohol (in 135 
the same evening), but not the day after nor the day before”. Responses were collected on a six-point 136 
scale (“almost always”, “often”, “more or less half of the time”, “seldom”, “hardly ever”, and 137 
“never”). Participants who answered “hardly ever” or more were considered as simultaneous users.  138 
On the 1,752 participants who used both alcohol and cannabis at baseline, 94.1% reported 139 
simultaneous use of alcohol and cannabis (n=1,649). The sample of concurrent alcohol and cannabis 140 
users was too small to perform network analyses. Missing values (n=90) were listwise-deleted, 141 
leading to our final sample of 1,559 participants, which represents 95% of the simultaneous alcohol 142 
and cannabis users at baseline. At follow-up, among the 1,577 alcohol and cannabis users, 94.9% 143 
reported simultaneous use (n=1,496). We deleted 24 missing values (n=1,472). The follow-up analysis 144 
included participants who were simultaneous users at both baseline and follow-up (n=991, 67.3% of 145 
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the follow-up sample) to see how alcohol and cannabis symptoms were associated for consistent 146 
simultaneous users over time. 147 
 148 
2.2 Measures 149 
Alcohol use disorder symptoms. Participants filled out questions related to the eleven criteria of the 150 
alcohol use disorder as reported in the DSM-5 (American Psychiatric Association, 30) for the twelve 151 
previous months (see symptoms in Table 1). Symptoms were collected on dichotomous scales, in 152 
terms of presence versus absence and collected at baseline and follow-up. The reliability of the scale 153 
was acceptable: Kuder-Richardson Formula 20 = .73 and Spearman Brown split-half correlation = .76. 154 
Cannabis use disorder symptoms. Respondents answered the ten criteria of the Cannabis Use 155 
Disorder Identification Test-Revised (31) for the twelve previous months. For each of the ten items, 156 
we recoded the responses into dichotomous symptoms: “never” = “absence”; “less than a month” or 157 
more = “presence”; for questions 1 and 2, the lowest category “less than a month” and “1 or 2 hours” 158 
were considered as “absence” and the other categories as “presence” (no use was not possible as 159 
people who complete the scale are cannabis users) instead of keeping the original four-point scale, 160 
this in order to consider equivalent dichotomous low-threshold measures for alcohol and cannabis 161 
(27). Symptoms were also collected at baseline and follow-up. The reliability of the scale was also 162 
acceptable: Kuder-Richardson Formula 20 = .74 and Spearman Brown split-half correlation = .82. 163 
Alcohol and cannabis use disorders were assessed in French or German. The psychometric 164 
properties were acceptable for both disorders and both languages. We performed confirmatory factor 165 
analyses for ordinal data (weighted least squares means and variances, WLSMV estimation) to 166 
confirm the single factor for alcohol and cannabis use disorders. Analyses were conducted separately 167 
for French and German languages using Mplus 7. Fit indices were acceptable: root mean square error 168 
of approximation (RMSEA) ranged between .030 and .082, comparative fit index (CFI) between .969 169 
and .984, and weighted root mean square residual (WRMR) between 0.858 and 1.519. 170 
2.3 Data analysis 171 
After computing descriptive statistics for alcohol and cannabis use disorder symptoms, we 172 
estimated the symptoms’ network structure with the IsingFit method in R (32). This method is 173 
designed for binary variables. It computes pairwise conditional associations between nodes, with a 174 
penalty weight to shrink the smalls coefficients to zero (33). The network estimation combines L1-175 
regularized logistic regression with model selection using the Extended Bayesian Information 176 
Criterion (32). To transform raw data into an adjacency matrix, two parameters are computed: an 177 
interaction parameter (which provides the strength of the interaction between two variables) and the 178 
node parameter (which gives the autonomous preference for each variable to take the value 1). These 179 
parameters are computed using iterative logistic regressions, each variable being regressed on all 180 
others, with a L1-penalty imposed on each regression coefficient. Variables are defined as nodes 181 
(vertices in the adjacency matrix) and relevant relationships between nodes as edges (undirected 182 
graph). 183 
To investigate whether symptoms of alcohol and cannabis use disorders were separate from one 184 
another, we applied community detection analysis to identify the clusters of symptoms in the global 185 
network of alcohol and cannabis symptoms, based on the walktrap community finding algorithm. 186 
This algorithm identifies densely connected subgraphs using short random walks (34). 187 
Finally, to identify potential bridge symptoms between alcohol and cannabis use disorders, we 188 
computed bridge centrality indices (35). They indicate whether some symptoms have notable 189 
relationships with the other cluster of symptoms. Bridge strength is defined as the sum of the absolute 190 
weights of a focal symptom with all symptoms that are not in the same cluster. Bridge betweenness 191 
is the number of shortest paths going through a focal symptom that connect pairs of symptoms from 192 
different clusters. Bridge closeness is the inverse of the sum of shortest distances from a focal 193 
symptom to all other symptoms in the other cluster. Symptoms with high scores on bridge centrality 194 
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indices indicate potential bridge symptoms, connecting symptoms of alcohol and cannabis use 195 
disorders. A higher score indicates a more important bridge centrality. 196 
We checked for model accuracy using the recommended analysis (36): edges weight accuracy. 197 
The edge weight accuracy was tested by drawing bootstrapped 95% confidence intervals. 198 
Overlapping confidence intervals between the different edges of the network mean that even if some 199 
edges may seem stronger, they are actually not significantly different. It does not affect the 200 
interpretation of the edges’ presence: an edge between two nodes means that the corresponding 201 
symptoms are connected. No test of model accuracy is available for bridge centrality indices, so these 202 
results should be interpreted carefully. 203 
All analyses were performed twice: first a baseline network, including symptoms of alcohol and 204 
cannabis at baseline for baseline simultaneous use; and second a follow-up network, including 205 
symptoms at follow-up. In the second analysis, we used the subsample of participants who were 206 
simultaneous users of alcohol and cannabis at baseline and follow-up (n=991).  207 
As a sensitivity analysis, we tested networks using the same symptoms for the two disorders 208 
(and excluding items that were not assessed for both disorders), namely: excessive use, continued 209 
use, loss of control, loss of interest, withdrawal, health consequences, and social consequences 210 
(alcohol tolerance, craving for alcohol, frequency of cannabis use, and cannabis mood modification 211 
were not included). The results were very similar to those presented below, so we kept the whole 212 
scales for both disorders. Data are available upon request to the corresponding author. We also tested 213 
other cut-off scores to dichotomize the CUDIT scale, with similar results. 214 
We used R 3.3.2 for all analyses, with the package IsingFit 0.3.1 and qgraph 1.4.2 to visualize 215 
networks (37), the algorithm “walktrap.community” from the igraph 1.0.1 package to detect 216 
community, the package networktools 1.1.1 to compute bridge centrality indices, and the package 217 
bootnet 0.4 for bootstrap estimations (36). 218 
3. Results 219 
Participants were on average 20.0 ± 1.2 years at baseline (21.3 ± 1.2 at follow-up); 57.6% were 220 
French-speaking, and 42.4% were German-speaking. Percentages of symptom endorsement are 221 
reported in Table 1.  222 
 223 
Table 1. Percentages and bridge centrality of alcohol and cannabis use disorder symptoms. 224 
  Baseline (n=1,559) Follow-up (n=991) 
Label Items % 
Bridge 
strength 
Bridge 
betweenness 
Bridge 
closeness 
% 
Bridge 
strength 
Bridge 
betweenness 
Bridge 
closeness 
A1 
Neglect important 
activities 
20.9 0.60 8 0.23 
19.5 0.33 5 0.24 
A2 
Increased chances of 
getting injured 
45.4 0.00 0 0.18 
46.6 0.00 0 0.13 
A3 
Resume drinking 
habits despites 
problems with others 
8.1 0.50 11 0.28 
6.5 0.00 0 0.27 
A4 Tolerance 34.2 0.07 0 0.19 27.4 0.00 0 0.22 
A5 Withdrawal 6.9 2.09 69 0.40 4.7 0.00 0 0.16 
A6 
Drink more/longer 
than intended 
43.0 0.28 0 0.18 
51.2 0.00 0 0.17 
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A7 
Try to cut down but 
couldn't 
5.8 0.00 9 0.25 
5.5 0.63 54 0.35 
A8 
Spend time obtaining, 
using, recovering from 
alcohol 
26.6 0.12 2 0.19 
27.0 0.00 4 0.18 
A9 Give up activities 5.0 0.00 14 0.26 4.5 0.37 17 0.25 
A10 
Continue drinking 
despites health 
problems 
5.4 0.72 3 0.22 
3.8 0.00 18 0.20 
A11 
Strong desire or urge 
to drink 
6.0 0.00 0 0.24 
6.0 0.00 0 0.15 
C1 
Frequency of cannabis 
use previous 12 
months 
48.6 1.11 0 0.24 
100* - - - 
C2 
Felt "stoned" after 
using cannabis ≥ 3 
hours 
37.4 0.00 0 0.21 
47.4 0.00 0 0.16 
C3 
Felt "stoned" for ≥ 6 
hours  
46.3 0.00 11 0.24 
52.3 0.00 11 0.18 
C4 
Being not able to stop 
using cannabis  
20.3 0.00 13 0.24 
18.9 0.00 0 0.22 
C5 
Failed to do what is 
expected  
36.0 0.43 3 0.21 
35.2 0.33 17 0.25 
C6 
Need of cannabis in 
the morning after a 
heavy cannabis intake  
16.6 1.36 64 0.31 
12.9 0.00 18 0.22 
C7 
Felt guilty or 
remorseful  
29.3 0.00 0 0.20 
27.6 0.00 0 0.18 
C8 
Had a problem with 
memory/concentration  
39.3 0.51 2 0.22 
36.8 0.00 0 0.21 
C9 
Refrained from leisure 
activities  
18.4 0.47 0 0.20 
18.9 0.00 0 0.18 
C10 
Had difficulties at 
work/school  
12.4 0.50 4 0.23 
8.8 1.00 78 0.31 
A: alcohol, C: cannabis. 225 
* This symptom was not included in the network analysis because it has no variance (symptom endorsed by all 226 
participants). 227 
 228 
Baseline network 229 
The association between cannabis and alcohol symptoms at baseline is presented in Figure 1, 230 
where we can see that few relationships linked alcohol and cannabis symptoms. The community 231 
detection analysis confirmed that the network was separated in two clusters, corresponding to the 232 
symptoms of alcohol use for the first one and cannabis use for the second. There were eleven positive 233 
edges, on the 110 possible ones, between the symptoms of the two disorders. Therefore, only 10.0% 234 
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of the possible edges connected the symptoms of two disorders. There were also two negative edges. 235 
The edge weight accuracy suggested that the strength of the edges should be compared cautiously 236 
because of overlapping confidence intervals, but within-cluster edges tended to be significantly 237 
higher than between-cluster edges (data available on request).  238 
Results on the centrality bridge indices of the symptoms (see Table 1) indicated that withdrawal 239 
connected the clusters of alcohol and cannabis symptoms (A5 and C6). These symptoms were 240 
potential bridge symptoms between the two clusters. 241 
 242 
 243 
Figure 1. Network of alcohol and cannabis symptoms at baseline (n=1,559).  244 
A1-A11: symptoms of alcohol use disorder, C1-C10: symptoms of cannabis use disorder (see Table 1 245 
for labels). Green (or red) paths are positive (or negative) regularized logistic regression weights. 246 
Thicker edges indicate a stronger relationship between symptoms. Node colors are defined according 247 
to the community detection analysis. 248 
 249 
Follow-up network 250 
The network of alcohol and cannabis symptoms at follow-up for participants who were 251 
simultaneous users at both baseline and follow-up is reported in Figure 2. The community detection 252 
analysis identified three clusters. Alcohol and cannabis symptoms were again separate clusters, and 253 
there was in addition two distinct clusters for alcohol use disorder. There were only three positive 254 
edges between alcohol and cannabis, i.e., 2.7% of all possible relationships between the two disorders. 255 
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The edge weight accuracy suggested that the strength of the edges should be compared cautiously 256 
because of overlapping confidence intervals.  257 
Centrality bridge indices are reported in Table 1 (bridge indices were computed between alcohol 258 
use disorder including its two clusters and the cluster of cannabis use disorder). Withdrawal was no 259 
longer a potential bridge symptom between the disorders. Symptoms with the highest bridge indices 260 
were trying to cut down alcohol (A7) and difficulties in school/work related to cannabis use (C10). 261 
 262 
 263 
Figure 2. Network of alcohol and cannabis symptoms at follow-up (n=991).  264 
A1-A11: symptoms of alcohol use disorder, C1-C10: symptoms of cannabis use disorder (see Table 1 265 
for labels). Green paths are positive regularized logistic regression weights. Thicker edges indicate a 266 
stronger relationship between symptoms. Node colors are defined according to the community 267 
detection analysis. 268 
 269 
4. Discussion 270 
By investigating symptoms irrespectively of their disorders’ boundaries (22, 23), this research 271 
provided a new vision of the comorbidity between symptoms of alcohol and cannabis use disorders 272 
among young men from a population-based sample who used them simultaneously.  273 
Our exploratory study showed that simultaneous alcohol and cannabis use was a frequent 274 
pattern of substance use in young adulthood, which was not associated to a common syndrome of 275 
substance use disorder. Indeed, the network analyses highlighted that symptoms of cannabis and 276 
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alcohol use disorders were separate clusters with only a small number of paths connecting the two 277 
disorders. Overall, these results mitigated findings of recent studies suggesting that cannabis and 278 
alcohol use are interacting disorders (15). If the disorders were interacting among simultaneous 279 
alcohol and cannabis users, we could expect strong between-disorders relationships, but it was not 280 
the case. Moreover, we could not highlight long-term associations between the disorders. Previous 281 
studies did not investigate direct relationships between the disorders and often focused on treatment 282 
outcomes such as abstinence and substance use-related problems. On the contrary, when studying 283 
direct relationships between symptoms from a network perspective, alcohol and cannabis use 284 
disorders did not appear as a unitary syndrome (12).  285 
The most important relationship between the disorders at baseline was related to withdrawal 286 
symptoms. We identified alcohol and cannabis withdrawal as possible paths between disorders. 287 
When simultaneous users refrain from using alcohol and cannabis at the same time, they may 288 
experience several withdrawal symptoms (e.g., depressed mood, irritability, anxiety, sleep difficulty) 289 
that are not specific to alcohol or cannabis. Therefore, it is possible that disentitling alcohol- and 290 
cannabis-related withdrawal was not possible, resulting in a strong relationship between these two 291 
symptoms at baseline. Another explanation might be that individuals who experiment alcohol 292 
withdrawal use cannabis to cope with withdrawal symptoms (or the opposite). However, this 293 
relationship was no longer highlighted at follow-up. As the replicability of centrality indices has been 294 
criticized, further studies should focus on withdrawal symptoms to test again our baseline findings 295 
(38-40). This limitation does not affect the network structure (i.e., presence of edges and clusters), 296 
because the global characteristics of the network models have been described as consistent across 297 
methods and samples (38). In addition, our follow-up analysis showed that our findings on the 298 
separate clusters for alcohol and cannabis use disorders seemed robust.  299 
One important difference between previous studies and our study was that we did not focus on 300 
a clinical sample but on a population-based sample of young Swiss men. Clinical samples are often 301 
biased, since only a small proportion of addicted users seek for help and treatment. Using large 302 
samples from the general population to assess substance use disorders is probably a reliable way to 303 
reach all sorts of substance users and to get a general picture of the relationships between alcohol and 304 
cannabis use. Our results are in line with previous research based on population-based samples 305 
showing that cannabis users respond similarly to alcohol interventions as non-cannabis users (41). 306 
This also suggested that alcohol and cannabis use are not strongly interacting conditions.        307 
Focusing on simultaneous users seems crucial for future researches in the addiction field, in both 308 
population-based and clinical samples. Clinical trials designed to evaluate substance abuse treatment 309 
often exclude multiple drug users and focus on a single-drug use type (8, 42). Since multiple drug 310 
use is common and harmful, it should not been seen as a hindrance in clinical trials (43). The insights 311 
of this research may also be of use from a clinical perspective and to provide guidance for substance 312 
abuse treatment. Drug abuse treatment programs traditionally recommend complete abstinence 313 
because of a fear that users will switch to another substance (15, 44). Indeed, the absence of abstinence 314 
is often described as a barrier to treatment, leading to delays in treatment initiation and relapse (15). 315 
Besides, it is likely to decrease the willingness to seek treatment among users of these substances (10). 316 
Our results on the relative independence of the two conditions among simultaneous users may be 317 
useful to develop guidance for substance use treatment.  318 
In the current state of the art, studies using network-based analyses mainly focused on group-319 
level networks (45). An interesting contribution of the network perspective is to identify symptoms 320 
that may predict the development of the disorder(s), i.e., symptoms that are highly connected in the 321 
network. These symptoms may provide early warning signals usable at the individual level and may 322 
thus have direct therapeutic implications (17). The network perspective appears as a helpful 323 
complement to standard analyses to guide clinical decision-making and treatment (46). 324 
This study had some shortcomings. A first limitation was that the study only included men in 325 
their earlies twenties and substance use behaviors are distinct for women (47). Data among women 326 
and older adults are needed to confirm our findings. Meanwhile, we should consider our conclusions 327 
as preliminary ones. A second limitation was that the study used self-reported scales, which may 328 
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cause response bias and misunderstanding of the symptoms, especially for alcohol (48). Young 329 
people are likely to misinterpret survey questions and share a misperception of alcohol symptoms, 330 
such as aftereffects and acute intoxication. Therefore, they might overreport physiological symptoms 331 
of withdrawal and tolerance (49). For example, tolerance is often over-reported in self-reported data. 332 
In our network, over-reporting symptoms might have lead to an artificial increase of relationships 333 
between symptoms. Another important limitation was that we used different tools to assess alcohol 334 
and cannabis use disorders. Even if we addressed this issue using a sensitivity analysis selecting 335 
common symptoms, further studies should use the same criteria for both disorders. In addition, the 336 
CUDIT also includes questions that are not symptoms of cannabis use disorder (e.g., felt stoned after 337 
using cannabis for three hours or more) and some symptoms considered low use (lower than monthly 338 
use and felt stoned for one or two hours) as “absence”. However, the sensitivity analysis focusing on 339 
the same symptoms for both disorders yielded similar results. Therefore, we are confident that our 340 
findings can be interpreted as investigating relationships between symptoms of the two disorders. 341 
Further studies are needed to confirm our results and should include women, use clinical interviews, 342 
as well as different populations such as older adults or treatment-seeking populations (50). 343 
Furthermore, comparisons between simultaneous and concurrent users would provide more 344 
evidence of influence of simultaneous use on the relationship between disorders, beyond our 345 
descriptive findings (are the relationships between disorders stronger for simultaneous users 346 
compared to concurrent users or not?). 347 
5. Conclusions 348 
In conclusion, this study showed that alcohol and cannabis use disorders were distinct clusters 349 
of symptoms in the network analysis, suggesting thereby that they were not interacting disorders. 350 
Overall, network-based analyses appeared to be a promising new research perspective in mental 351 
health research, which emphasize the relationships between and within mental health disorders.  352 
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